Recurrent Squamous Cell Lung Carcinoma Clinical Trial
Official title:
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02536495 -
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02785939 -
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02965378 -
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT03373760 -
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
|
Phase 2 | |
Completed |
NCT02785913 -
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
|
Phase 2 | |
Completed |
NCT03377556 -
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02926638 -
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
|
Phase 2/Phase 3 | |
Completed |
NCT02154490 -
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
|
||
Completed |
NCT02766335 -
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
|
Phase 2/Phase 3 | |
Terminated |
NCT00946712 -
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02785952 -
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
|
Phase 3 |